The First Placebo-Controlled Trial in Cryopyrin-Associated Periodic Syndromes (CAPS): IL-1 Trap (rilonacept) Markedly Reduces Clinical and Laboratory Abnormalities in Patients with Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS)

Primary efficacy endpoints were change in disease activity (rash, fever/chills, joint pain, eye redness/pain, and fatigue) scores. There was a greater incidence of injection site reaction (mostly mild) and upper respiratory tract infection (mild to moderate) with IL1T.

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2007-02, Vol.119 (2), p.524-524
Main Authors: Hoffman, H.M, Weinstein, S.P, Amar, N.J, Throne, M.L, Boling, E.P, Grimes, I.M, Belomestnov, P, Stein, D.R, Vicary, C, Mellis, S.J
Format: Article
Language:English
Subjects:
Allergy and Immunology
Medical research
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Primary efficacy endpoints were change in disease activity (rash, fever/chills, joint pain, eye redness/pain, and fatigue) scores. There was a greater incidence of injection site reaction (mostly mild) and upper respiratory tract infection (mild to moderate) with IL1T.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2006.12.631